Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Conferences and Medical Updates



Tuesday, December 8, 2015



Cardiac resync therapy with Defibrillator helps morbidity mortality in HF ( CRT-D)



SPRINT trial

Sunday, November 22, 2015



hat said, he pointed out that in patients without chronic kidney disease (CKD) at baseline, there was a decline of at least 30% in estimated GFR in 1.21% of the intensive-therapy group per year vs 0.35% of the standard-therapy group (P<0.0001). “This could be due to the well-known renal hemodynamic reactions of more ARBs or more ACE inhibitors at higher doses. But still, that seems rather a large number.” Also, 4.1% vs 2.5% of each respective group had acute kidney injury (AKI). “We don’t know why and really look forward to seeing a more detailed analysis of the renal outcomes,” said Rosendorff.

Complementary With ACCORD

As reported by heartwire , the >9000-person SPRINT trial of hypertensive patients at increased CV risk showed that targeting systolic blood pressure of less than 120 mm Hg rather than the standard target of less than 140 mm Hg was associated with significantly lower risks of the primary composite end point (MI, ACS, stroke, acute decompensated HF, and CV death), as well as all-cause mortality and CV death.

However, there were also significantly higher rates of hypotension, syncope, and AKI in the intensive-therapy group, which received roughly three antihypertensive medications, vs the standard therapy group, which received an average of two antihypertensives.



CHF nsaid mineralocorticoid receptor antagonist

Thursday, September 3, 2015



LONDON — The investigational non-steroidal mineralcorticoid receptor antagonist finerenone worked as well as eplerenone (Inspra) with a possible mortality advantage over the older drug in heart failure, the phase II ARTS-HF trial suggested.

Reductions in NT-proBNP of more than 30% from baseline to day 90, the study’s primary endpoint, occurred in 37.2% of eplerenone-treated patients compared with 30.9% to 38.8% of finerenone-treated patients across doses tested (P not significant), Gerasimos Filippatos, MD, of Athens University Hospital Attikon in Greece, and colleagues found.